Clinical BenefitsBicara's drug is showing potentially best-in-class overall clinical benefits in hard to treat HPV negative patients.
Clinical OutcomesThe combination of ficerafusp alfa 1500mg + Keytruda elicited a 54% confirmed overall response rate and a 21% complete response rate in the total evaluable study population, which appears meaningfully superior to results from similar patient populations.
Financial PerformanceBicara ended 2Q25 with cash, cash equivalents, and marketable securities of $436.6M, which should be sufficient to fund operations significantly beyond major upcoming data catalysts.